Determinants of drug prices and expenditures

Managerial and Decision Economics

Volumn 28, Issue 4-5, 2007, Pages 357-370

  Comanor, William S ^a,b   Schweitzer, Stuart O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548361996     PISSN: 01436570     EISSN: 10991468     Source Type: Journal    
DOI: 10.1002/mde.1346     Document Type: Article

References (32)

1. Berndt ER. 1994. Uniform Pharmaceutical Pricing: An Economic Analysis. American Enterprise Institute: Washington, DC.
2. Berndt ER. 2001. The U.S. pharmaceutical industry: why major growth in times of cost containment? Health Affairs 20: 107.
3. Berndt ER, Cockburn IM, Griliches Z. 1996. Pharmaceutical innovations and market dynamics: tracking effects on price indexes for antidepressant drugs. Brookings Papers: Microeconomics; 174.
4. Clark LT. 1991. Improving compliance and increasing control of hypertension: needs of special hypertensive populations. American Heart Journal 121: 664.
5. Comanor WS, Schweitzer SO. 1994. Pharmaceuticals. In Structure of American Industry (9th edn), Adams W, Brock JW (eds). Prentice Hall: Englewood Cliffs, NJ; 179.
6. Comanor WS, Schweitzer SO, Carter T. 2005. A hedonic model of pricing innovative pharmaceuticals, In Health Policy and High-Tech Industrial Development: Learning from Innovation in the Health Industry. DiTommaso MR. Schweitzer SO (eds). Edward Elgar Publishers: Cheltenham.
7. Cooper JK, Love DW, Raffoul PR. 1982. Intentional prescription nonadherence (noncompliance) by the elderly. American Geriatrics Society 30: 329.
8. Danzon P. Chao L-W. 2000. Across national price differences for pharmaceuticals: how large, and why? Journal of Health Economics 19: 159-195.
9. Danzon PM, Pauly MV. 2002. Health insurance and the growth in pharmaceutical expenditures. Journal of Law and Economics XLV: 590 [Table 1].
10. Department of Health and Human Services. 1999. Health United States.
11. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation, new estimates of drug development and costs. Journal of Health Economics 22: 151-180.
12. Esposito D. 2003. You get what you co-pay for: the influence of patent co-payments on the demand for drugs. Doctoral Dissertation, Department of Economics, University of California, Santa Barbara.
13. Feldstein PJ. 1993. Health Care Economics (4th edn), Delmar: Albany, NY.
14. Frank R, Salkever D. 1992. Pricing patent loss and the market for pharmaceuticals. Southern Economic Journal 50: 165-179.
15. Giaccotto C, Sonterre RE. Vernon JA. 2005. Drug prices and research and development investment behavior in the pharmaceutical industry, Journal of Law and Economics XLVIII.
16. Goldman DP, Joyce GF, Escarce JJ, Pace JE, Solomon MD, Laouri M, Landsman PB, Teutsch SM. 2004, Pharmacy benefits and the use of drugs by the chronically ill. Journal of the American Medical Assoication 291: 2344-2350.
17. Griliches Z, Cockburn IM. 1994. Generics and new goods in the pharmaceutical price indexes. American Economic Review, 84.
18. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. 2003. The effect of incentive-based formularies on prescription drug utilization and spending. New England Journal of Medicine 349: 2224-2232.
19. Kaiser Family Foundation. 2004. Prescription drug trends-update. Publication Number: 3057-03.
20. Kessler D, Rose JL, Temple RJ et al. 1994. Therapeutic class wars-drug promotion in a competitive marketplace. The New England Journal of Medicine 331: 1350-1353.
21. Lu ZJ, Comanor WS. 1998. Strategic pricing of new pharmaceuticals. Review of Economics and Statistics 80.
22. National Institute for Health Care Management. 1999. Issue Brief: factors affecting growth of prescription drugs expenditures.
23. Payer L. 1988. Medicine and Culture: Varieties of Treatment in the United States, England, West Germany, and France. Penguin: New York.
24. Pharmaceutical Research and Manufacturers Association. 2004. Annual Report 2004-2005. Pharmaceutical Research and Manufacturers Association, Washington, DC.
25. Salehi H, Schweitzer S. 1985. Economic aspects of drug substitution. Health Care Financing Review 6(5): 59-68.
26. Scherer FM. 2001. The link between gross probability and pharmaceutical R&D spending. Health Affairs 20.
27. Steiner RL. 1993. The inverse association between the margins of manufacturers and retailers. Review of Industrial Organization 8: 717-740.
28. United States Congress, General Accounting Office. 1992. Prescription drugs: companies typically charge more in the United States than in Canada. GAO/HRD-92-110, 30 September.
29. United States Congress, General Accounting Office. 1994. Prescription drugs: companies typically charge more in the United States than in the United Kingdom. GAO/HEHS-94-29, 12 January.
30. United States General Accounting Office. 1992, Prescription drugs changes in prices for selected drugs. GAO/HRD-92-128; 1.
31. US Congress. Office of Technology Assessment. 1993. Pharmaceutical R&D: costs, risks and rewards, OTA-H-522. US Government Printing Office: Washington, DC.
32. Wiggins SN, Maness R. 2004. Price competition in pharmaceuticals: the case of anti-infectives. Economic Inquiry 42(2): 247-263.